MarginsXMarginsX
Home › Markets › Health Care › GMAB

Genmab A/S ADS (GMAB)

GMAB trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$51.57
+0.39% on the day
Market cap
$32.2B
Large cap
Revenue · 2025
$3.7B
+19.2% on 2024
Net income · 2025
$963.0M
25.9% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1434265/000143426526000014/0001434265-26-000014-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerGMAB on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryDenmark
IPO year2019
SEC CIK0001434265
SEC industry codePharmaceutical Preparations

Financials · 2025

LineValue
Revenue$3.7B
Net income$963.0M
Operating income$1.1B
Net margin25.9%
Operating margin28.6%
Revenue growth+19.2%
Cash$1.7B
Total assets$12.9B
P/E (computed)33.4×
P/S (computed)8.7×

Warning signs

Cash runway
Cash-flow positive
$1.7B cash at December 31, 2025
Share count, 1 year
See the dilution note
Going-concern doubt
No
20-F filed February 17, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-02-17
Cash and burn$1.7B cash; operating cash flow $296.5M a quarter.Report 2025-12-31
Shares outstanding642,384,080 (2025-12-31). the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte Statsautoriseret Revisionspartnerselskab, Copenhagen, DenmarkPCAOB Form AP 2026-03-24
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
$3.7B$963.0M$1.2B$1.7B$5.3B$3.7B20-F 2026-02-17
FY 2024
2024-12-31
$3.1B$1.1B$1.1B$1.4B$0$3.1B20-F 2026-02-17
FY 2023
2023-12-31
$2.4B$631.0M$1.1B$2.2B$0$2.4B20-F 2026-02-17

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B42019-07-19
Latest annual report20-F2026-02-17
Latest quarterly / interim6-K2026-11-12

Source: SEC EDGAR submissions feed, 573 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-4.2%
1 month+40.5%
3 months+63.9%
Year to date+66.8%
1 year+69.9%
From 52-week high-10.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ZTSZoetis Inc.$84.39+0.68%$34.3B
ROIVRoivant Sciences Ltd. Common Shares$38.61-2.33%$28.0B
INSMInsmed Incorporated$122.88+1.42%$27.0B
RPRXRoyalty Pharma plc Class A Ordinary Shares$68.53-1.13%$39.3B
UTHRUnited Therapeutics Corporation$587.88-0.56%$25.0B
VTRSViatris Inc.$20.74-0.38%$23.8B
ONCBeOne Medicines Ltd.$411.29-1.26%$47.0B
ALNYAlnylam Pharmaceuticals Inc.$159.73-3.22%$21.4B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier